UNSPSC 51162301: Acetaminophen/chlorpheniramine/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162301 Acetaminophen/chlorpheniramine/phenylephrine/pyrilamine is a Commodity code that in recent state and local procurement does not align with its nominal pharmaceutical scope — the recent solicitations posted against this code instead seek naloxone, drug deactivation systems, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing channels. State and local health departments, counties, and purchasing cooperatives issue opportunities under this code to stock emergency medical supplies, community health initiatives, and institutional pharmacy inventories. The work involves procuring finished pharmaceutical products and related medical equipment from manufacturers or authorized distributors, subject to FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, and specific packaging and shelf-life requirements.

Recent activity shows Seminole County, Florida issuing an IFB on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posting an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. The Minnesota cooperative procurement emphasizes price competitiveness (75 percent evaluation weight), cGMP and DSCSA compliance, and flexible pricing formats (flat price, net price variants, or WAC-minus structures), with contracts effective July 1, 2026 and running two years for new vendors.